Navigation Links
Lexicon Pharmaceuticals to Present at Morgan Stanley Global Healthcare Conference
Date:9/6/2011

THE WOODLANDS, Texas, Sept. 6, 2011 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced today that Arthur T. Sands, M.D., Ph.D., Lexicon's president and chief executive officer, will present at the Morgan Stanley Global Healthcare Conference in New York City on Wednesday, September 14, 2011 at 9:10 a.m. Eastern Time.  Dr. Sands will provide an overview on Lexicon's clinical development programs and milestones.

A live webcast of the event may be accessed on Lexicon's corporate website at www.lexpharma.com.  An archived version of the webcast will be available for 30 days after the event on the company's website.

About Lexicon

Lexicon is a biopharmaceutical company focused on discovering breakthrough treatments for human disease.  Lexicon currently has four drug programs in mid-stage development for diabetes, irritable bowel syndrome, carcinoid syndrome and rheumatoid arthritis, all of which were discovered by Lexicon's research team.  Lexicon has used its proprietary gene knockout technology to identify more than 100 promising drug targets.  Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs.  For additional information about Lexicon and its programs, please visit www.lexpharma.com.

Safe Harbor Statement

This press release contains "forward-looking" statements, including statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct preclinical and clinical development of its potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2010, as filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Lexicon Pharmaceuticals to Present at Stifel Nicolaus Healthcare Conference
2. Lexicon Pharmaceuticals to Present at the Wedbush 2011 Life Sciences Management Access Conference
3. Lexicon Announces Publication of Results From the Phase 2 Trial of LX1031 in Patients With Irritable Bowel Syndrome in Journal of Gastroenterology
4. Phase 2 Trial of Lexicons LX1032, Telotristat Etiprate, Shows Positive Results in Carcinoid Syndrome
5. Lexicon Pharmaceuticals Reports on Clinical Program Status and 2011 Second Quarter Results
6. Lexicons IBS Drug Candidate, LX1033, Successfully Completes Phase 1 Clinical Trial
7. Lexicon Presents LX4211 Mechanism of Action Data at American Diabetes Association Meeting and Announces Commencement of Phase 2b Clinical Trial in Type 2 Diabetes
8. Lexicon Pharmaceuticals Announces Webcast of 2011 Annual R&D Day
9. Lexicon Pharmaceuticals Reports on Clinical Program Status and 2011 First Quarter Results
10. Lexicon to Provide First Quarter 2011 Financial Results
11. Lexicon Pharmaceuticals Appoints Dr. Pablo Lapuerta Chief Medical Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... , Aug. 15, 2017 Diplomat Pharmacy, ... to Michigan residents. ... Flint retail pharmacy, G-3320 Beecher Road. ... by the Food and Drug Administration, is intended to ... drowsiness, slowed breathing, and loss of consciousness. The medication ...
(Date:8/11/2017)... CAESAREA, Israel , Aug. 11, 2017 ... company with mobile health and big data solutions, today ... results on Monday, August 14 and host a conference ... second quarter 2017 operating and financial results and its ... call will be hosted by Erez Raphael , ...
(Date:8/7/2017)... Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), ... Board of Directors has approved the payment of a quarterly ... The cash dividend of ... 27, 2017 to stockholders of record as of the close ... are subject to approval of the Board of Directors and ...
Breaking Medicine Technology:
(Date:8/21/2017)... ... August 22, 2017 , ... The ... as a 2017-2018 inductee into its VIP Woman of the Year Circle. She ... nation’s leading networking organization exclusively for professional women, boasting more than 850,000 members, ...
(Date:8/21/2017)... MINNEAPOLIS, MINN (PRWEB) , ... August 21, 2017 ... ... Sports Group, today announced that it has become the Official Technology Partner of ... their AES (Advanced Event Systems) volleyball software, along with providing sport ...
(Date:8/21/2017)... ... August 21, 2017 , ... Duncan ... program serving the people of Michigan. The new initiative fundraises for the Kalamazoo ... the very forefront of animal protection and welfare by addressing the root causes ...
(Date:8/21/2017)... ... ... The American Hospital Association (AHA) has elected Claire Zangerle, Chief Nurse Executive ... of Trustees for a three-year term beginning January 1, 2018. , The ... are committed to the improvement of health in their communities. Founded in 1898, the ...
(Date:8/21/2017)... ... ... The Industrial Designers Society of America (IDSA) hosted the ... Aug. 19, 2017 in Atlanta, GA—revealing which 25 designs won Gold and which 52 ... See all the winners at http://www.idsa.org/awards/idea/gallery . , “I hope you’re as excited ...
Breaking Medicine News(10 mins):